APA (7th ed.) Citation

CY, C., WC, C., CP, L., CH, L., HY, C., WJ, W., . . . JL, K. (2025). Endoglin as a predictive biomarker for pemetrexed sensitivity in non-small-cell lung cancer: A cellular study. Cancer chemotherapy and pharmacology, 95(1), 20. https://doi.org/10.1007/s00280-024-04734-9

Chicago Style (17th ed.) Citation

CY, Cheng, Chuang WC, Lin CP, Li CH, Chang HY, Wu WJ, Wu MF, and Ko JL. "Endoglin as a Predictive Biomarker for Pemetrexed Sensitivity in Non-small-cell Lung Cancer: A Cellular Study." Cancer Chemotherapy and Pharmacology 95, no. 1 (2025): 20. https://doi.org/10.1007/s00280-024-04734-9.

MLA (9th ed.) Citation

CY, Cheng, et al. "Endoglin as a Predictive Biomarker for Pemetrexed Sensitivity in Non-small-cell Lung Cancer: A Cellular Study." Cancer Chemotherapy and Pharmacology, vol. 95, no. 1, 2025, p. 20, https://doi.org/10.1007/s00280-024-04734-9.